CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 128 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2023. The put-call ratio across all filers is 0.00 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $47,088,204 | +67.8% | 1,583,329 | +1.7% | 4.47% | +103.4% |
| Q2 2023 | $28,061,140 | +7.9% | 1,557,222 | -3.8% | 2.20% | -6.1% |
| Q1 2023 | $26,003,148 | +6.9% | 1,619,125 | +21.8% | 2.34% | +3.7% |
| Q4 2022 | $24,326,428 | -8.0% | 1,329,313 | -1.3% | 2.26% | -15.7% |
| Q3 2022 | $26,448,000 | +14.3% | 1,346,652 | +8.5% | 2.68% | -0.6% |
| Q2 2022 | $23,137,000 | +80.9% | 1,240,609 | +112.9% | 2.69% | +138.7% |
| Q1 2022 | $12,792,000 | +65.1% | 582,767 | +113.6% | 1.13% | +103.2% |
| Q4 2021 | $7,750,000 | – | 272,796 | – | 0.56% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |